Let’s conduct a quick thought experiment. We enter a time machine and set the controls for Connecticut in 2015. As luck would have it, we land in a meeting room of the imaging department at the Yale-New Haven Health system. There we overhear a conversation. Imaging aficionados that we are, we quickly realize two groups are present—IT leaders and ranking radiologists. It’s hard to make out the exact words through the time warp. However, we clearly hear one term repeated several times: “deconstructed PACS.” 

TAVR is increasingly seen as the preferred option for symptomatic severe aortic stenosis, and clinical guidelines in the U.S. reserve their highest recommendations for patients who experience symptoms. Asymptomatic patients, meanwhile, are typically managed by clinical surveillance or a “watch and wait” approach; no symptoms means no treatment.

As the leading provider of generic contrast agents, Fresenius Kabi’s commitment is to provide you with choice and value – by continuing to grow their radiology portfolio. We look forward to seeing you at RSNA 2025 | Booth #3247 | South Hall 

Six years ago, two radiologists with dissimilar backgrounds and divergent clinical interests put their heads together and launched a new practice. One physician was an academic subspecialized in musculoskeletal reads. The other, a private practitioner, concentrated on oncologic imaging. That’s how Transparent Imaging was born, powered by Konica Minolta. 

Identifying the signs of severe aortic stenosis is typically a fairly straightforward process for cardiologists. In some cases, however, the patient’s symptoms present in a way that is outside of the norm.